Hjem › Pladecellekræft i hoved og hals
Pladecellekræft i hoved og hals kliniske forsøg rekrutterer i USA
178 studier for Pladecellekræft i hoved og hals rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Houston, TX47 studier
- Los Angeles, CA42 studier
- Boston, MA40 studier
- Nashville, TN39 studier
- New York City, NY39 studier
- St. Louis, MO28 studier
- Arlington, VA26 studier
- Philadelphia, PA26 studier
- Chicago, IL26 studier
- Atlanta, GA24 studier
- Pittsburgh, PA22 studier
- New Haven, CT22 studier
- San Antonio, TX22 studier
- Dallas, TX20 studier
- Queens, NY20 studier
- Columbus, OH20 studier
- Portland, OR19 studier
- Cleveland, OH18 studier
- Durham, NC17 studier
- Orlando, FL16 studier
- Baldwin Park, CA16 studier
- Detroit, MI15 studier
- Edison, NJ15 studier
- Baltimore, MD15 studier
- Tampa, FL15 studier
- Grand Rapids, MI15 studier
- Cincinnati, OH14 studier
- Miami, FL14 studier
- San Diego, CA14 studier
- Charleston, SC14 studier
- Santa Monica, CA13 studier
- Milwaukee, WI13 studier
- Omaha, NE13 studier
- Oklahoma City, OK13 studier
- Rochester, MN12 studier
- Jacksonville, FL12 studier
- Richmond, VA12 studier
- Cedar Rapids, IA12 studier
- Ann Arbor, MI12 studier
- West Valley City, UT11 studier
Efter delstat
- Alabama7 studier
- Arizona18 studier
- Arkansas11 studier
- Californien72 studier
- Colorado23 studier
- Connecticut24 studier
- Delaware3 studier
- District of Columbia9 studier
- Florida53 studier
- Georgia26 studier
- Idaho4 studier
- Illinois30 studier
- Indiana13 studier
- Iowa14 studier
- Kansas9 studier
- Kentucky16 studier
- Louisiana6 studier
- Maryland18 studier
- Massachusetts42 studier
- Michigan36 studier
- Minnesota23 studier
- Missouri29 studier
- Montana5 studier
- Nebraska15 studier
- Nevada4 studier
- New Hampshire3 studier
- New Jersey26 studier
- New Mexico3 studier
- New York54 studier
- North Carolina27 studier
- North Dakota6 studier
- Ohio46 studier
- Oklahoma14 studier
- Oregon19 studier
- Pennsylvania41 studier
- Rhode Island7 studier
- South Carolina21 studier
- South Dakota9 studier
- Tennessee43 studier
- Texas69 studier
- Utah21 studier
- Vermont3 studier
- Virginia42 studier
- Washington18 studier
- Wisconsin15 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06992427FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06788990A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06465069Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06265285Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT05176483177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07189871A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07090499Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06589804A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07085091A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07814248A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07744126Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07360314A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT05877599A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
RekruttererFase 1
Alder 18 til 74 · Alle køn · Opdateret 25. sep. 2026 · NCT07219212BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05136196A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
RekruttererFase 3
Alder 60 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT04892173Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06980038A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06385080A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT07229313Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06047379Intratumoral N17350 in Advanced Solid Tumors
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07339176Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RekruttererFase 2
Alder 18 til 79 · Alle køn · Opdateret 22. sep. 2026 · NCT04671667Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT05983432Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT06736379Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.